SAN DIEGO, April 3, 2014 /PRNewswire/ -- Millennium Laboratories announced today that it has established an advisory board consisting of distinguished health care, technology and public policy experts to provide strategic guidance to the company. An established leader in the science of medication monitoring and pharmacogenetic testing, Millennium assembled the advisory board in an effort to further support company goals.
The announcement comes on the heels of the RxAnte acquisition, a health care predictive analytics and decision support company that improves population-level medication adherence. RxAnte is simultaneously extending relationships with two of its key advisors.
"We are proud to have the honor of working with such esteemed experts to contribute to our vision of improving quality of care and reducing waste in the system," said Brock Hardaway, CEO of Millennium Laboratories. "The guidance from these advisors, coupled with our recent acquisition of RxAnte, ultimately will help patients and physicians achieve better results through more personalized, effective treatments."
"Our advisors have had a significant and positive influence on RxAnte's products and services--and by extension, on the members and patients our clients serve," said Josh Benner, President of RxAnte. "Our entire team is excited to build on our relationship with these key individuals."
The companies anticipate joint meetings of their advisors, to build on their respective foundations in medication monitoring and advanced analytics. This, in turn, will help the companies develop innovative technologies, products and services to address payer, provider, and patient needs today and in the future.
New members of the Advisory Board include:
-- Senator Tom Daschle, a senior policy advisor in DLA Piper's Government Affairs practice. Sen. Daschle has participated in the development and debate of many major public policy issues of the last three decades. He is one of the longest serving Senate Democratic leaders in history and the only one to serve twice as both Majority and Minority Leader. He distinguished his experience in health care through the publication of "Critical: What We Can Do About the Health Care Crisis" and "Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform." He is the Chair of the DuPont Advisory Committee on Agriculture Innovation and Productivity, as well as the BP Tangguh Independent Advisory Panel. He also serves on the Health Policy and Management Executive Council at the Harvard School of Public Health, and is a member of the Council on Governance for Sustainability at the World Economic Forum and the Federal Advisory Board of Accenture. -- John Short, principal of Short Consulting LLC, a health care consulting firm. Dr. Short is also the former CEO of RehabCare Group, a rehabilitation services provider that was acquired by Kindred Health Care in 2011, and board member for WellPoint and its subsidiary CareMore. He started his first health care consulting firm nearly 45 years ago. Dr. Short serves on the Board of Directors of InteliStaf Holdings Inc., and is a member of the Board of Acute Long Term Hospital Association (ALTHA). He was formerly a member of the American Hospital Association's Post-Acute Presidents Forum, and was the managing partner of Phase 2 Consulting, serving large acute care health systems throughout the United States.
RxAnte advisors continuing their service on the Advisory Board include:
-- Dr. Mark B. McClellan, a senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. He is the founding chairman of the FDA's Reagan-Udall Foundation, is co-chair of the Quality Alliance Steering Committee, leads the National Quality Forum's partnership on applying clinician quality measures, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. Dr. McClellan previously served as a member of the President's Council of Economic Advisers, senior director for health care policy at the White House, and also advises U.S. government officials on health care policy issues. A physician and economist by training, he also has a highly distinguished record in public service and in academic research. -- Robert Pfotenhauer, MPH, the former CEO of four healthcare companies with more than 35 years of experience in health insurance and health care delivery. He began his career with Group Health Cooperative of Puget Sound in Seattle and in his final role, helped build the nation's leading Part D prescription drug company of United Health Group, serving more than 4.5 million Medicare members. He has also held executive roles with Group Health Association, Kaiser Permanente and VISICU.
About Millennium Laboratories and RxAnte
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, is transforming the way health care professionals monitor and manage their patients' medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at www.millenniumlabs.com.
RxAnte helps large healthcare organizations improve prescription drug use. The RxAnte System(TM) is a patent-pending analytics platform that includes predictive and decision analytics, advanced evaluation methods, and an innovative, cloud-based platform that equips health care professionals to improve medication outcomes for at-risk patients. More information is available at www.RxAnte.com.
SOURCE Millennium Laboratories